Skip to Content

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

HER2-targeted therapy, particularly known for breast cancer treatment, has in recent years gained traction in the treatment of gastroesophageal adenocarcinoma as well. In this article, based on a piece published by ASCO Daily News, we will provide a brief introduction to the developments in this field.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top